Of note, compared to patient data where KMT2Ar AML cells had higher SREBP2 expression than KMT2Ar ALL cells, the opposite was true for the commercially available KMT2Ar cell lines. This evidence concerns the gene SREBF2 and acute myeloid leukemia.